Wyeth Pharmaceuticals (Pennsylvania)
Worldwide Headquarters
500 Arcola Road
Collegeville
Pennsylvania
19426
United States
Tel: 610-902-1200
Website: http://www.wyeth.com/
About Wyeth Pharmaceuticals (Pennsylvania)
Wyeth is committed to helping people throughout the world lead healthier lives through the development of innovative pharmaceutical, consumer healthcare, vaccine and nutritional products. Our organization consists of Wyeth Pharmaceuticals, Wyeth Research, Wyeth Consumer Healthcare, Wyeth BioPharma, Fort Dodge, Solgar and SPL. Working together, the Wyeth family maintains active leadership in the pharmaceutical industry through a dedication to research and development, quality manufacturing, responsible sales, marketing and licensing alliances, educational programs and initiatives, and service to the health-care professional.
Wyeth is a Fortune 500 global enterprise servicing the health needs of people in more than 145 countries. Achieving over $14 billion in net revenue in 2001, Wyeth provides more prescription products to Americans than any other pharmaceutical company and offers one of the broadest and most diverse product lines in the industry. We are the leader in women's health care research and marketing and are among the top manufacturers of vaccine products in the United States.
Wyeth has a solid track record in the discovery, development, marketing and sales of innovative products that play a leading role in world health care. Our major research and development programs target the discovery and delivery of important drugs in the following therapeutic areas:
- Women's health care
- Central nervous system disorders
- Immunology
- Oncology
- Infectious diseases
Locations
Headquartered in Madison, NJ, Wyeth employs more than 40,000 people worldwide. In 2001, our divisions Wyeth Pharmaceuticals and Wyeth Research began moving into their new state-of-the-art corporate headquarters in Collegeville, Pennsylvania, located near Philadelphia. Phase II construction for our Collegeville facility will be ongoing throughout 2002.
Wyeth Research sites are located in Collegeville, Pennsylvania; Princeton, New Jersey; Pearl River and Chazy, New York; and Cambridge and Andover, Massachusetts. As a global leader in the pharmaceutical industry, Wyeth Research also maintains a strong international presence, with offices in Japan, Australia, Canada and throughout Europe. Wyeth Pharmaceuticals maintains state-of-the-art manufacturing facilities throughout the US, Canada and Puerto Rico and manages global affiliate company operations in countries throughout Europe, Asia, Africa, South America and the Pacific Rim. Wyeth Nutritionals has manufacturing facilities in Georgia, Vermont and other locations around the world.
Culture
Wyeth is dedicated to bringing results home. We have an outstanding and diversified group of professionals. Interaction, collaboration and responsible management make our workplace an exhilarating environment that leads to achievement and success. We take pride in our accomplishments. And we value people who not only seek answers, but raise questions, offer ideas and have the talent to lead us into the future. Benefits
Wyeth offers an attractive package of employee benefits including stock options (exempt positions only), a company-matched savings plan (401k), medical, dental, prescription and vision care plans, a dependent care spending account/assistance plan, childcare subsidies, business casual dress code, education assistance and professional development programs.
Current Highlights
Global Supply Chain Wyeth is currently expanding its Supply Chain organization. As a result we have openings at various Wyeth locations worldwide in such diverse areas as strategic planning, project management, purchasing, materials management, manufacturing, quality assurance and control, packaging, engineering, technical services, distribution and customer service.
The employees of our Supply Chain division are focused on achieving a high level of customer satisfaction by providing the timely delivery of quality products and services. Because of our dedicated employees, our customers can feel confident that they are getting the best products available as quickly as possible.
To learn more about Wyeth visit us at our newly enhanced web site at www.wyeth.com .
Wyeth is an Equal Opportunity Employer, and complies with all applicable federal, state and local laws regarding non-discrimination. Wyeth provides equal employment opportunities to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, national origin, age disability or status as a veteran.
Last Updated: 3-13-02
35 articles about Wyeth Pharmaceuticals (Pennsylvania)
-
Wyeth Pharmaceuticals Race Discrimination Ruling Highlights Forced Double Shifts at N.Y. Factory
4/2/2009
-
Wyeth Pharmaceuticals (Pennsylvania) and Santaris Pharma A/S Announce Strategic Alliance to Develop RNA-based Medicines; Santaris May Receive Payments of up to $83 Million
1/12/2009
-
Wyeth Pharmaceuticals (Pennsylvania) (JOBS) Seeks Obesity Treatment with $150 Million UK Buy
12/18/2008
-
Wyeth Pharmaceuticals (Pennsylvania) and Progenics Pharmaceuticals, Inc. Receive Approval from European Commission (EC) for RELISTOR for Opioid-Induced Constipation in Advanced Illness Patients
7/3/2008
-
Wyeth Pharmaceuticals (Pennsylvania) Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
6/4/2008
-
Wyeth Pharmaceuticals (Pennsylvania) Release: New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma - Data From Phase 3 Study Presented at American Society of Clinical Oncology
6/2/2008
-
Wyeth Pharmaceuticals (Pennsylvania) Release: New Analyses Presented at American Society of Clinical Oncology Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer - Data Showed Overall Survival Benefit With TORISEL Regardless
6/2/2008
-
Wyeth and Progenics Pharmaceuticals, Inc. Relistor Misses Goal In Improving Gastrointestinal Function After Surgery
5/22/2008
-
Medidata Solutions, Inc.'s Medidata Rave Selected by Wyeth Pharmaceuticals (New Jersey) for Enterprise-Wide EDC Deployment
10/23/2007
-
Wyeth Hot Flashes Drug Succeeds in Trial-Research
10/8/2007
-
Wyeth Pharmaceuticals (Pennsylvania) and Progenics Pharmaceuticals, Inc. Initiate New Clinical Studies to Investigate Additional Patient Populations for Methylnaltrexone
9/11/2007
-
Wyeth and Progenics Pharmaceuticals, Inc. Submit Marketing Application in Australia for Subcutaneous Methylnaltrexone
8/29/2007
-
Crucell N.V. Announces PER.C6(R) and AdVac(R) Technology License Agreement with Wyeth Pharmaceuticals
7/30/2007
-
Wyeth Pharmaceuticals (Pennsylvania) Begins Marketing and Distributing BeneFIX in Europe
7/3/2007
-
Amgen and Wyeth Pharmaceuticals (Pennsylvania) Release: ENBREL Safety Data for up to Eight Years in Patients with Juvenile Rheumatoid Arthritis Being Presented at EULAR
6/13/2007
-
Wyeth Announces Results of Highly Successful Implementation of Closed Loop Marketing at 2007 EyeforPharma Sales Force Effectiveness Conference
3/13/2007
-
Decoding Alzheimer's
1/9/2007
-
Catalyst Biosciences, Inc. And Wyeth Pharmaceuticals Sign Two Agreements For Novel Biotherapeutic Platform Of Engineered Proteases
1/8/2007
-
Progenics Pharmaceuticals, Inc. Earns $5 Million From Wyeth For Achieving Methylnaltrexone Milestone
10/25/2006
-
First Prempro Suit Goes To Trial In Ark.T
8/21/2006